Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PROTACing the androgen receptor and other emerging therapeutics in prostate cancer.

Expert review of anticancer therapy - 1 Sept 2024

Zang Peter D, Seylani Allen, Yu Evan Y, Dorff Tanya B

Abstract excerpt

INTRODUCTION: The androgen receptor (AR) is a critical driver of prostate cancer progression, and the advent of androgen receptor pathway inhibitors (ARPIs) has transformed the treatment landscape of metastatic prostate cancer. However, resistance to ARPIs eventually develops via mutations in AR, AR overexpression, and alternative AR signaling which have required novel approaches to target effectively. AREAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Proteolysis
Share to Androgen Receptor Antagonists
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Molecular Targeted Therapy

Share to Prostatic Neoplasms

Share to Receptors, Androgen

Share to Signal Transduction

Source

Identifiers

PMID: 39021245
DOI: 10.1080/14737140.2024.2379913

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PROTACing the androgen receptor and other emerging therapeutics in prostate cancer.PMID 39021245Read ↗

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancerSemantic proximity Read ↗

PROTACs in the Management of Prostate Cancer.Semantic proximity Read ↗

The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on TherapySemantic proximity Read ↗

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical ApplicationsSemantic proximity Read ↗

Constitutive activity of the androgen receptor.Semantic proximity Read ↗

Androgen receptor: past, present and future.Semantic proximity Read ↗

Androgen receptor plasticity and its implications for prostate cancer therapy.Semantic proximity Read ↗

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancerSemantic proximity Read ↗

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerSemantic proximity Read ↗

Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatmentSemantic proximity Read ↗

Mechanisms of resistance to androgen deprivation therapy in prostate cancer.Semantic proximity Read ↗

Targeting the androgen receptor and overcoming resistance in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.